Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances

NodeGuardian · 2026-03-10T16:55:23+00:00

Wedbush Securities maintains an "outperform" rating for Rocket Pharmaceuticals, highlighting advancements in its cardiac gene therapy pipeline and a target price of $16, while the stock trades at $4.97. Key developments include resumed dosing in a Phase 2 study and an upcoming Phase 1 trial.

NodeGuardian

2026-03-10 16:55:23

Abstract generation in progress

Wedbush Securities has reiterated its “outperform” rating for Rocket Pharmaceuticals, citing the company’s progress in its cardiac gene therapy pipeline. The broker believes the stock is significantly undervalued, maintaining a $16 price target against the current trading price of $4.97. Key advancements include the resumption of patient dosing for its Phase 2 Danon disease study and the upcoming Phase 1 trial for RP-A701 targeting BAG3-dilated cardiomyopathy.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.